ABSTRACT: Despite the fact that the teratogenic effects of phenytoin have been suggested in several case reports, the evidence for a possible oncogenic potential of phenytoin has not been widely recognized. Recently, neuroblastoma as well as other neuroectodermal and non-ectodermal tumors has been seen in several children exposed to phenytoin prenatally. Previous cases have been almost uniformly associated with the features of "fetal hydantoin syndrome" and none have been developmentally normal. We report a developmentally-normal boy of 2'/2 years with an abdominal neuroblastoma whose mother had been on phenytoin (as well as carbamazepine) throughout gestation. We review the various neoplasms which have been reported in the offspring of mothers receiving phenytoin. RESUME: Neuroblastome et exposition fetale a la phenitoine chez un enfant sans trait dysmorphique. En depit du fait que les effets te>atogenes de la phenitoine ont ete suggeres dans plusieurs observations de cas, les indications que la phenitoine a possiblement un potentiel oncogene n'ont pas ete largement reconnues. Recemment, le neuroblastome ainsi que d'autres tumeurs d'origine neuro-ectodermique et non-ectodermique ont ete observees chez plusieurs enfants exposes a la phenitoine a la periode prenatale. Les cas anterieurs ont et6 presque tous associ^s aux manifestations du "syndrome fetal de I'hydantoine" et aucun n'a eu un developpement normal. Nous rapportons le cas d'un gar9on de deux ans et demi dont le developpement etait normal et qui avait un neuroblastome abdominal. Sa mere avait pris de la phenitoine (ainsi que de la carbamazepine) pendant toute la grossesse. Nous revoyons les diffeYents n6oplasmes qui ont 6t6 rapportes chez les enfants de meres recevant de la phenitoine.
Neuroblastoma, a neural crest tumor, has been reported recently in the offspring of epileptic mothers who were exposed to phenytoin and other antiepileptic drugs.
1 " 6 Phenytoin was incriminated as the most likely oncogenic agent in most cases because all the children who developed a neuroblastoma were also affected by a combination of malformations which has been termed the fetal hydantoin syndrome (FHS). 5 It is now recognized however that a similar pattern of malformations or anomalies can occur with maternal use of other antiepileptic drugs besides phenytoin. 7 This is the first report of a neuroblastoma in a developmentally-normal child who was exposed prenatally to phenytoin (as well as carbamazepine).
CASE REPORT A 2'/2 year-old boy was admitted to the Children's Hospital of Eastern Ontario for the investigation of an abdominal mass. He had also been febrile and had a recent otitis media. His mother had been on phenytoin 300-350 mg/day throughout the gestation and for 8 years prior for idiopathic epilepsy with generalized tonic-clonic and complex partial seizures. The one phenytoin level obtained during gestation was 5 Ttmol/ml. She had also been taking carbamazepine 800-1000 mg/day (level 19 Ttmol/ml) throughout the pregnancy. She was not exposed to alcohol and tobacco during gestation. Seizures were completely controlled during pregnancy. The child's birth and developmental milestones were normal. There were no detectable congenital malformations or anomalies.
Examination revealed a normocephalic child with no dysmorphic features. His weight was 14.6 kg. He had shotty cervical lymphadenopathy and a firm, immobile, right upper quadrant abdominal mass. CT scan showed a calcified tumor invading the right kidney and displacing liver, aorta and the inferior vena cava. A spot urine vanilyl mandelic acid was positive. Bone marrow examination confirmed the diagnosis of neuroblastoma stage IV. He was started on chemotherapy and he was doing relatively well 8 months following the diagnosis.
DISCUSSION
The teratogenic effect of phenytoin has been extensively investigated although its role has not been definitively dissociated from that of other antiepileptic drugs. There is likely a two to three-fold increased risk of malformations and anomalies such as cleft lip and palate, ventricular septal defect, distal digital hypoplasia, other digital anomalies and microcephaly in children exposed to phenytoin in utero. 7 The rarely seen full-blown "fetal hydantoin syndrome" (FHS) also includes other minor malformations and in some cases mental retardation. 8 A number of single case reports suggest that prenatal phenytoin exposure is associated with an increased incidence of neuroblastoma'" 6 and other neuroectodermal childhood neoplasms. 10 10 Additionally, 4 non-neuroectodermal neoplasms were recently reported (1 mesenchymoma, 1 Hodgkins disease, 1 rhabdomyosarcoma and Wilms' tumor), all occurring in dysmorphic children except the rhabdomyosarcoma which occurred in a normal child (Table 2) . 13 " 16 In 4 of the 12 children with neoplasia exposed to antiepileptic drugs in utero, phenytoin was the only agent involved, while in the other 8 cases, it was used in combination with other drugs (or alcohol).
Our patient represents the first reported case of neuroblastoma in a physically normal child who was exposed to antiepileptic drugs prenatally. Ependymoblastoma is the only other neuroectodermal neoplasm reported in a physically normal child exposed to phenytoin in utero. 12 This observation suggests that, if phenytoin is oncogenic, the mechanisms involved are possibly separate from those related to its teratogenic effect.
Phenytoin has been linked to benign lymphoid hyperplasia and malignant lymphoma in adults presumably through effects on the immune system. 12 Experimental studies investigating the oncogenic potential of phenytoin in animals were inconclusive and suffered from methodological flaws. 1718 The possible transplacental oncogenicity of phenytoin has not been studied in experimental animals. Epoxides (arene oxides), intermediate metabolites of phenytoin in some patients as well as of carbamazepine have been reported to be oncogenic as well as mutagenic. 1920 The ability of arene oxides and their derivatives to bind covalently to RNA and DNA provides a possible molecular None basis for the oncogenicity of these metabolites. 21 Concurrent carbamazepine therapy in our case may have produced increased concentrations of phenytoin arene oxide metabolites through microsomal enzyme induction. There is no evidence suggesting a genetic link between neuroblastoma and idiopathic epilepsy.
We cannot exclude a chance relationship between prenatal phenytoin exposure and neuroblastoma in this case or even a possible relationship to carbamazepine exposure. Koren et al. have pointed out that, on the basis of their own survey of 189 cases of neuroblastoma and data available from the U.S. Collaborative Perinatal Project, there does not appear to be an increased association between neuroblastoma and phenytoin exposure in developmentally normal children. 6 Of twenty-eight children diagnosed with neuroblastoma in the Quebec screening project since May, 1989, none were known to have been exposed to phenytoin or other antiepileptic drugs in utero (B. Lemieux, personal communication). However, the accumulating number of case reports of primitive neoplasms, some of them quite rare, in the offspring of mothers taking phenytoin during gestation is worthy of attention.
Offspring of mothers exposed prenatally to phenytoin should be closely examined for both teratogenic and oncogenic effects. Children with the fetal hydantoin syndrome should be carefully examined for neoplasia. A complete gestational drug history should be sought in children with neuroblastoma and other neoplasms. Further evidence should be sought, both prospectively and retrospectively for the oncogenic potential of antiepileptic drug exposure in utero.
